echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Zhong Nanshan: Two antibody kits approved to help distinguish influenza and new coronary pneumonia virus

    Zhong Nanshan: Two antibody kits approved to help distinguish influenza and new coronary pneumonia virus

    • Last Update: 2020-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    China News Agency, Guangzhou, Feb 23 (CAI Minjie) Zhong Nanshan, academician of the Chinese Academy of engineering, held a remote consultation with Guangdong counterpart medical team of Jingzhou Medical University in Guangzhou on Feb 23 Zhong Nanshan said that according to the current data, the epidemic situation in Jingzhou has begun to change Jingzhou should focus on the treatment of critical patients and improve the cure rate At the meeting, Zhong Nanshan said that the number of new cases in Hubei Province on Tuesday was 630, with the absolute number of new cases falling Novel coronavirus pneumonia cases were confirmed in 630 cases in February 22nd, from 0 to 24 in February 22nd, including 8 cases in Jingzhou China's novel coronavirus pneumonia has also been approved by the State Administration of drug administration, one of which is a reagent for identifying influenza, new crown pneumonia and parainfluenza, "Zhong Nan Shan said." this is a key task In addition, two more qualified antibody kits are approved, "one of them is Wanfu biology from Guangdong Province, both of which are colloidal gold methods, which can detect LGM antibody in patients, and can detect LGM antibody on the 7th day of infection or the 3rd day of disease, which is very helpful for further diagnosis of patients." Zhong Nanshan said Novel coronavirus products were novel coronavirus products from 3 enterprises, including 2 colloidal gold antibody detection reagents and 1 isothermal amplification chip detection methods, which expanded the detection methods and means of new coronavirus on the 22 day The approval of the China National Drug Administration was approved by the State Administration of pharmaceuticals for emergency examination on the 3 th.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.